RSLV-145 is a first-in-class drug candidate with dual RNase and DNase enzyme activities, that is prolonged in serum circulation by the IgG1 Fc domain.  The molecule is designed to digest DNA and RNA found in the systemic circulation bound to autoantibodies as well as freely circulating nucleic acids from necrotic cells.  Nucleic acids trigger major RNA and DNA sensors of the immune system in response to viral infection.  DNA and RNA maintained in the circulation through binding to autoantibodies constantly presents these nucleic acids to the immune system mimicking a viral infection which results in chronic inflammation characteristic autoimmune diseases.  Removal of the nucleic acids bound to autoantibodies is thought to render the autoantibodies inert thereby eliminating chronic inflammation associated with several major autoimmune diseases.